
Karijn P M Suijkerbuijk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8906490/publications.pdf Version: 2024-02-01



KADIIN D M SHIIKEDBIIIK

#	Article	IF	CITATIONS
1	Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer Immunology, Immunotherapy, 2023, 72, 249-255.	4.2	5
2	Survival of stage IV melanoma in Belgium and the Netherlands. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
3	Discontinuation of <scp>antiâ€PD</scp> â€1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. International Journal of Cancer, 2022, 150, 317-326.	5.1	12
4	The unfavorable effects of <scp>COVID</scp> â€19 on Dutch advanced melanoma care. International Journal of Cancer, 2022, 150, 816-824.	5.1	18
5	Nipple Aspirate Fluid at a Glance. Cancers, 2022, 14, 159.	3.7	7
6	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. Cancer, 2022, 128, 2746-2752.	4.1	12
7	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	30.7	121
8	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research, 2022, 32, 460-468.	1.2	7
9	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. BMC Cancer, 2022, 22, .	2.6	0
10	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. Cancer Immunology, Immunotherapy, 2021, 70, 1491-1496.	4.2	15
11	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
12	First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis. British Journal of Cancer, 2021, 124, 1222-1230.	6.4	16
13	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. European Journal of Cancer, 2021, 144, 242-251.	2.8	16
14	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519.	4.2	14
15	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. BMC Cancer, 2021, 21, 323.	2.6	22
16	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	1.6	28
17	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 641-648.	3.9	46
18	High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. European Journal of Cancer, 2021, 149, 105-113.	2.8	4

KARIJN P M SUIJKERBUIJK

#	Article	IF	CITATIONS
19	TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out. Nature Reviews Rheumatology, 2021, 17, 505-505.	8.0	5
20	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	3.7	11
21	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
22	Checkpoint inhibition: protecting against or predisposing for second primary tumors?. Annals of Oncology, 2021, 32, 935.	1.2	4
23	Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. European Journal of Cancer, 2021, 158, 208-216.	2.8	33
24	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	3.7	9
25	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	2.8	12
26	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 1345-1346.	3.9	4
27	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	3.7	1
28	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 2021, 31, 58-66.	1.2	6
29	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open, 2021, 6, 100320.	4.5	10
30	The importance of timely treatment for quality of life and survival in patients with symptomatic spinal metastases. European Spine Journal, 2020, 29, 3170-3178.	2.2	12
31	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open, 2020, 5, e000945.	4.5	14
32	Validation of the Dutch version of the Edmonton Symptom Assessment System. Cancer Medicine, 2020, 9, 6111-6121.	2.8	16
33	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	3.7	16
34	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. Journal of Immunotherapy, 2020, 43, 256-264.	2.4	17
35	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	3.7	11
36	Realâ€world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. International Journal of Cancer, 2020, 147, 3461-3470.	5.1	27

KARIJN P M SUIJKERBUIJK

#	Article	IF	CITATIONS
37	Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors. JAMA Oncology, 2020, 6, 1300.	7.1	4
38	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 2020, 12, 1003.	3.7	15
39	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry. Clinical Cancer Research, 2020, 26, 2268-2274.	7.0	112
40	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. Frontiers in Oncology, 2020, 10, 585311.	2.8	69
41	The impact of frailty on the occurrence of immune-related adverse events in older patients with advanced melanoma Journal of Clinical Oncology, 2020, 38, e24028-e24028.	1.6	Ο
42	Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition. European Journal of Cancer, 2019, 121, 1-3.	2.8	2
43	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	1.6	83
44	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. Cancers, 2019, 11, 1940.	3.7	29
45	Dark ascites, an ovarian mass and a black dotted peritoneum. Netherlands Journal of Medicine, 2019, 77, 124.	0.5	Ο
46	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 579-588.	1.4	11
47	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist, 2017, 22, 709-718.	3.7	221
48	Diarrhoea during checkpoint blockade, not always colitis. European Journal of Cancer, 2017, 87, 216-218.	2.8	10
49	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	1.8	24
50	Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study. PLoS ONE, 2015, 10, e0127895.	2.5	11
51	Improving early breast cancer detection: focus on methylation. Annals of Oncology, 2011, 22, 24-29.	1.2	53
52	Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer. Familial Cancer, 2010, 9, 321-325.	1.9	22
53	Low Levels of <i>BNIP3</i> Promoter Hypermethylation in Invasive Breast Cancer. Analytical Cellular Pathology, 2010, 33, 175-176.	1.4	6
54	Molecular Analysis of Nipple Fluid for Breast Cancer Screening. Pathobiology, 2008, 75, 149-152.	3.8	26

#	Article	IF	CITATIONS
55	Oxytocin: bringing magic into nipple aspiration. Annals of Oncology, 2007, 18, 1743-1744.	1.2	18